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Abstract
Background:  Cyclooxygenase-2 (COX-2) expression has previously been identified in uveal
melanoma although the biological role of COX-2 in this intraocular malignancy has not been
elucidated. This study aimed to investigate the effect of a COX-2 inhibitor on the proliferation rate
of human uveal melanoma cells, as well as its effect on the cytotoxic response of macrophages.
Methods: Human uveal melanoma cell lines were transfected to constitutively express COX-2 and
the proliferative rate of these cells using two different methods, with and without the addition of
Amfenac, was measured. Nitric oxide production by macrophages was measured after exposure
to melanoma-conditioned medium from both groups of cells as well as with and without Amfenac,
the active metabolite of Nepafenac.
Results: Cells transfected to express COX-2 had a higher proliferation rate than those that did
not. The addition of Amfenac significantly decreased the proliferation rate of all cell lines. Nitric
oxide production by macrophages was inhibited by the addition of melanoma conditioned medium,
the addition of Amfenac partially overcame this inhibition.
Conclusion: Amfenac affected both COX-2 transfected and non-transfected uveal melanoma cells
in terms of their proliferation rates as well as their suppressive effects on macrophage cytotoxic
activity.
Introduction
Uveal melanoma is the most common primary intraocu-
lar tumor in adults. The ability of ophthalmologists to
diagnose the primary tumor has increased from an aver-
age accuracy of 87.5 percent in 1980 [1] to approximately
99.5 percent in 1990 [2]. This increase in diagnostic
accuracy reflects better training, and the introduction of
new clinical tools such as A and B scan ultrasound. As
diagnosis has improved so too has local treatment, with
the development of radiotherapy a much more conserva-
tive option than the previous standard treatment of enu-
cleation. There is, however no difference between
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mortality rates of patients treated with either of these local
therapies [3]. A patient who now presents with this dis-
ease continues to have the same 10-year mortality rate of
approximately 40% as those who were diagnosed three
decades ago [4]. It is therefore apparent that a further
understanding of the cellular mechanisms behind this dis-
ease and its metastatic processes are required in order to
identify novel prognostic factors and targets for systemic
therapy that will affect patient prognosis.
Several prognostic factors of uveal melanoma, such as cell
type, have been utilized for decades. More recently identi-
fied prognostic factors include tumor associated macro-
phages (TAM) which have been shown to be a predictor of
poor prognosis in uveal melanoma [5]. The activity of
these TAM in the tumor and the possible immunosup-
pression of the macrophages by tumour-secreted factors
has previously been studied in cutaneous melanoma [6].
The effect of uveal melanoma-secreted factors on the cyto-
toxic activity of macrophages has not yet been investi-
gated. The demonstration that cyclooxygenase-2 (COX-2)
inhibition can reverse melanoma induced suppression of
macrophage cytotoxic activity in cutaneous melanoma
[6], is of interest as COX-2 expression has recently been
identified in uveal melanoma [7].
COX-2 is not only a prognostic factor but also a potential
therapeutic target in uveal melanoma. There are three iso-
forms of the COX enzyme. COX-1 is expressed constitu-
tively in normal tissues [8]. COX-2 is an inducible enzyme
expressed in response to a variety of inflammatory and
mitogenic stimuli [9]. COX-2 expression has been
reported in a wide variety of malignant tumors [10-12],
including uveal melanoma [7], where it was correlated
with predictors of poor prognosis. The expression of COX-
2 has been linked to various processes including tumor
proliferation [13], immunosuppression [14] and metasta-
sis [15,16]. Specific COX-2 inhibitors are currently in use
for patients diagnosed with familial adenomatous poly-
posis, a genetic disorder that predisposes patients to
colonic adenocarcinomas [17]. The effectiveness of these
selective inhibitors has been investigated in a variety of
tumors and shows promise for use as an adjuvant therapy
in the treatment of many tumor types [18].
The aim of this study was to investigate the possible role
of COX-2 expression and inhibition by a COX-2 inhibitor
(Nepafenac) on the proliferation rates of human uveal
melanoma cell lines. In addition, we wished to investigate
the effect of soluble factors secreted by human uveal
melanoma cell lines on the cytotoxic activity of macro-
phages. Amfenac, a COX-2 inhibitor formulated for topi-
cal administration to the eye [19,20], was investigated in
terms of its effects on macrophage cytotoxicity in response
to soluble factors secreted by uveal melanoma cell lines.
Methods
Cell Culture
Four previously characterized human uveal melanoma
cell lines (92.1, SP6.5, MKT-BR, OCM-1) and one human
transformed uveal melanocyte cell line (UW-1) were incu-
bated at 37°C in a humidified 5% CO2-enriched atmos-
phere [21]. The cells were cultured in RPMI-1640 medium
(Invitrogen, Burlington, Ontario, Canada), supplemented
with 5% heat inactivated fetal bovine serum (FBS), 1%
fungizone, and 1% penicillin-streptomycin purchased
from Invitrogen (Burlington, Ontario, Canada). Cells
were cultured as a monolayer in 25 cm2 flasks (Fisher,
Whitby, Ontario, Canada) and observed twice weekly, at
every media change, for normal growth by phase contrast
microscopy. The cultures were grown to confluence and
passaged by treatment with 0.05% trypsin in EDTA
(Fisher) at 37°C and washed in 7 ml RPMI-1640 media
before being centrifuged at 120 g for 10 minutes to form
a pellet. Cells were then suspended in 1 ml of medium
and counted using the Trypan Blue dye exclusion test for
use in all subsequent assays.
The uveal melanoma cell lines 92.1, SP6.5, and MKT-BR
were established by Dr. Jager (University Hospital Leiden,
The Netherlands), Dr. Pelletier (Laval University, Quebec,
Canada) and Dr. Belkhou (CJF INSERM, France), respec-
tively. Dr. Albert (University of Wisconsin-Madison, USA)
established the OCM-1 and UW-1 cell lines [22,23].
Transfection with COX-2
The four human uveal melanoma cell lines and one trans-
formed melanocyte cell line were transfected to constitu-
tively express COX-2 using lipofectAMINE® as per the
manufacturer's recommendations (Invitrogen). Briefly, 1
× 105 cells were seeded in a 10 cm petri dish. Cells were
then allowed to incubate overnight. The pcDNA3 plasmid
(Invitrogen) encodes for resistance to Geneticin. This plas-
mid, with COX-2 cDNA inserted at the XBA I cleavage site,
was used at a concentration of 2 ug per 10 ul of Lipo-
fectAMINE in 100 ul of serum-free OptiMem medium
(Invitrogen). The cells were incubated for four hours with
this solution. After removal of the solution, cells were
grown in 5% FBS supplemented RPMI-1640 medium
with 400 ug/ml of Geneticin (G418, Gibco). Cells were
also transfected with the empty pcDNA3 plasmid and
compared to the original non-transfected cell lines as
controls.
Western blot and Immunohistochemistry
COX-2 expression was verified by Western blot and
immunohistochemistry performed on cytospins of the
five cell lines.
Western blot analysis was done as previously described
[24]. Briefly, protein samples from the cell lines wereJournal of Carcinogenesis 2007, 6:17 http://www.carcinogenesis.com/content/6/1/17
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prepared using 100 ul of 2× electrophoresis sample buffer
(250 mM TRIS pH 6.8, 4% SDS, 10% glycerol, 0.006%
bromophenol blue, 2% beta mercaptoethanol) per mil-
lion cells, which was then boiled for 5 minutes. The same
number of cells per sample was used. Proteins were sepa-
rated on 12% SDS-Page gel and transferred to a polyvi-
nylidene difluoride membrane overnight (Amershame
bioscience, Piscataway, NJ, USA). The membrane was
blotted for specific antibody according to Proto Blot for
Western blot alkaline phosphatase system (Promega Cor-
poration, Ontario, Canada). The primary antibody, mon-
oclonal mouse anti-human COX-2 (Zimed Laboratories,
San Francisco, CA, USA; clone COX 229), was used at a
concentration of 3 ug/ml. The secondary, a goat anti-
mouse alkaline phosphatase-conjugated antibody
(Sigma-Aldrich, Ontario, Canada) was used to visualize
the proteins on the membrane. Cell lysate from macro-
phages stimulated with interferon gamma and LPS (Trans-
duction Laboratories, BD Biosciences, San Diego, CA,
USA) was used as a positive control. A broad range molec-
ular weight marker (BioRad) was used. Equal protein
loading of cell extracts in SDS-Page was determined by
Bio-Rad protein assay solution.
The cytospin slides were removed from -20°C and left at
room temperature overnight before being fixed with 2%
paraformaldehyde for 30 min. The paraformaldehyde-
fixed samples were then tested for COX-2 expression by
immunocytochemical analysis using a monoclonal
mouse anti-COX-2 antibody (Zimed Laboratories, San
Francisco, CA, USA; clone COX 229) at a dilution of 1:50.
Immunohistochemistry was performed using the Ventana
BenchMark fully automated staining machine with a sam-
ple of cutaneous melanoma as a positive control.
Proliferation assay
The Sulforhodamine-B based assay (TOX-6, Sigma-
Aldrich, St. Louis, Missouri, USA) was performed accord-
ing to the National Cancer Institute protocol [25]. Each of
the transfected and non-transfected cell lines was seeded
into wells at a concentration of 2.5 × 103 cells per well,
with a minimum of six wells per cell line. A row of 8 wells
containing only RPMI-1640 medium was used as a con-
trol. Cells were allowed to adhere overnight. The active
metabolite of Nepafenac, amfenac, was added to each
well at its IC50 of 150 nM [26]. Cells were then allowed
to incubate for 48 hours following the addition of
Amfenac. Following this 48-hour period, cells were fixed
to the bottom of the wells using a solution of 50%
Trichloroacetic acid (TCA) for 1 hour at 4°C. Plates were
then rinsed with distilled water, to remove TCA and
medium and air dried. The Sulforhodamine-B dye solu-
tion was then added to each well and allowed to stain for
25 minutes. The Sulforhodamine-B solution was subse-
quently removed by washing with a 10% acetic acid
solution and once again allowed to air dry. The dye that
had become incorporated into the fixed cells at the bot-
tom of the wells was solubilized in a 10 mM solution of
Tris. The absorbance of the solute was measured using a
microplate reader at a wavelength of 510 nm. Cells trans-
fected with only the pcDNA3 plasmid were used as con-
trols and did not significantly differ from the original
non-transfected cell lines.
For flow cytometry cell cycle analysis, cells were passaged
and counted as described previously [27]. Cell pellets
were resuspended in 1 ml of RPMI 1640 medium at a con-
centration of 1 × 106 cells/ml. The cells were labelled with
propidium iodide and a measurement of the cellular DNA
was then performed using an Epics XL flow cytometer
(Beckman Coulter, Miami, Florida). The percent of cells in
the S phase fraction (SPF) were then recorded for each of
the three replicates and averaged together.
Macrophage NO Production Assay
The four human uveal melanoma cell lines (92.1, MKT-
BR, OCM-1, SP6.5) and the transformed melanocyte cell
line (UW-1) with and without COX-2 transfection, as well
as one monocyte cell line (28SC), were seeded in 6 well
plates at a concentration of 1 × 106 cells/ml in 5% FBS
supplemented RPMI-1640 medium. Eighteen hours after
seeding the melanoma cells, medium was removed from
each well and centrifuged at 120 g for 10 minutes to
remove cells. The supernatant was then used as melanoma
conditioned medium (MCM). 28SC was then exposed to
MCM from the transfected and non-transfected cell lines
with and without amfenac at the recommended IC50 of
150 nM. 28SC incubated in fresh medium was used as
control. Twenty-four hours after media transfer, 28SC
were stimulated with 100 U/ml of Interferon gamma
(IFNγ) and 100 ng/mL of lipopolysacharide (LPS). The
experiment was done in triplicate. After 24 hours of stim-
ulation supernatants were removed and assayed for nitrite
levels using the Greiss reaction. One hundred μl of
medium was reacted with an equal mixture of 1% sulph-
anilamide and 0.1% naphthylethylenediamine dihydro-
chloride in 2.5% phosphoric acid. The mixture was
incubated at room temperature for 10 minutes and then
the absorbance was read at 550 nm using a BioTek EL 800
microplate reader (Fisher). Readings were compared to a
standard curve to calculate nitrite levels.
Statistical Analysis
The Student's t-test was used to compare proliferation
results between transfected and non-transfected cell lines,
as well as the same cell lines exposed to amfenac. It was
also used to compare results of 28SC incubated with con-
ditioned medium from COX-2 transfected versus non-
COX-2 transfected melanoma cell lines as well as 28SC
incubated with conditioned medium from these cell linesJournal of Carcinogenesis 2007, 6:17 http://www.carcinogenesis.com/content/6/1/17
Page 4 of 9
(page number not for citation purposes)
with and without amfenac. Flow cytometry results were
compared using a one-way ANOVA test with LSD post hoc
analysis
Results
COX-2 expression
Neither the five human uveal melanoma cell lines nor the
macrophage cell line constitutively expressed detectable
levels of COX-2 as measured by western blot analysis
(Figure 1) or immunohistochemsitry. All uveal
melanoma cell lines were positive for COX-2 expression
following transfection, with no apparent difference in
expression between the five transfected cell lines.
Proliferation Assays
With the Sulforhodamine-B assay, an increase (p < 0.05)
in proliferation was seen in four of the cell lines express-
ing COX-2 (92.1, MKT-BR, SP6.5, UW-1), while a decrease
in proliferation was seen in one cell line (OCM-1) as com-
pared to their non-transfected counterparts (p < 0.05).
The addition of amfenac inhibited the proliferation of all
cell lines (p < 0.05), with an inhibition that ranged
between 20–22% for all cell lines including OCM-1.
Figure 2 shows the difference in proliferation rate between
the COX-2 expressing and non-transfected cell lines as
well as the decrease in proliferation for all cell lines
treated with amfenac. The empty pcDNA3 plasmid trans-
fected cells did not show any change in proliferation as
compared to the original cell lines.
The percentage of cells in the S phase fraction (SPF%) is
shown in Table 1. A statistically significant (p < 0.05)
increase in SPF% was seen for each cell line that was trans-
fected to express COX-2. There was a decrease SPF% for
each cell line exposed to amfenac, with a larger decrease
in SPF% seen in those cells transfected to express COX-2.
Macrophage NO Production Assay
As compared to control medium, MCM from the four
uveal melanoma cell lines significantly reduced macro-
phage production of NO (p < 0.001). The addition of con-
ditioned medium from UW-1, the transformed
melanocytic cell line, yielded no significant decrease in
NO production by macrophages. Different levels of mac-
rophage NO production were seen with the MCM from
different uveal melanoma cell lines. As a result the
different MCMs could be ranked according to their
differential effects on macrophage NO production (most
macrophage NO production UW-1 > OCM-1 > MKT-BR >
92.1 > SP6.5 least macrophage NO production).
As compared to control medium, conditioned medium
from the uveal melanoma cell lines transfected to express
COX-2 also significantly decreased macrophage NO pro-
duction (P < 0.001). This decrease in macrophage NO pro-
duction was significantly different than that caused by
medium from the non-transfected cell lines. The addition
of conditioned medium from the COX-2 transfected UW-1
cell line yielded a significant decrease in NO production (P
< 0.001) as compared to control medium. The addition of
conditioned medium from the COX-2 transfected UW-1
cell line also yielded a significant decrease in NO produc-
tion (P < 0.0006) as compared to MCM from the non-trans-
fected UW-1 cell line. The different MCMs from COX-2
transfected cell lines could be ranked according to their dif-
ferential effects on macrophage NO production (most mac-
rophage NO production OCM-1 > UW-1 > MKT-BR > 92.1
> SP6.5 least macrophage NO production).
The addition of amfenac to the MCM of the four uveal
melanoma cell lines resulted in increase in macrophage
NO production as compared to MCM without amfenac
from the same cell lines. This increase was seen with MCM
from both transfected and non-transfected uveal
melanoma cell lines, with the exception of the non-trans-
fected OCM-1 cell line. The addition of amfenac to the
MCM of both transfected and non-transfected UW-1 cells
caused an increase in macrophage NO production as
compared to MCM without amfenac from the same cell
lines. Figures 3 and 4 show the relative macrophage
NO production with MCM from both transfected and
Western blot showing COX-2 expression Figure 1
Western blot showing COX-2 expression. Lane 1: molecular 
weight marker, weights are given in kilo daltons, lane 2 the 
positive control for COX-2 at 70 kDa, lane 3 the 92.1 cell 
line, lane 4 the 92.1 transfected cell line, lane 5 the MKT-BR 
cell line, lane 6 the transfected MKT-BR cell line, lane 7 the 
OCM-1 cell line, lane 8 the transfected OCM-1 cell line, lane 
9 the SP6.5 cell line, lane 10 the transfected SP6.5 cell line, 
lane 11 the UW-1 cell line, and lane 12 the transfected 
UW-1 cell line.Journal of Carcinogenesis 2007, 6:17 http://www.carcinogenesis.com/content/6/1/17
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Graph of proliferation rates of four human uveal melanoma cell lines (92.1, MKT-BR, OCM-1, SP6.5) and the UW-1 trans- formed melanocytic cell line, with and without addition of amfenac Figure 2
Graph of proliferation rates of four human uveal melanoma cell lines (92.1, MKT-BR, OCM-1, SP6.5) and the UW-1 trans-
formed melanocytic cell line, with and without addition of amfenac. RPMI alone was used as a control.
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Table 1: The fraction of cells in S phase as measured by flow cytometry (± standard deviation) for both the original cell line and the 
COX-2 transfected cell line with and without exposure to amfenac.
Cell Line Control SPF% SPF% with Amfenac
92.1 14.9 ± 0.8 11.2 ± 0.1
92.1 COX-2 30.2 ± 1.2 12.1 ± 0.6
MKT-BR 15.7 ± 0.6 13.2 ± 0.4
MKT-BR COX-2 29.6 ± 2.1 14.2 ± 0.6
OCM-1 18.4 ± 1.6 17.1 ± 1.2
OCM-1 COX-2 19.3 ± 0.9 15.8 ± 1.3
SP6.5 13.6 ± 0.7 11.3 ± 0.8
SP6.5 COX-2 41 ± 3.8 18.9 ± 0.2
UW-1 12.5 ± 1.1 10.2 ± 0.9
UW-1 COX-2 34.6 ± 2.5 15.8 ± 1.5Journal of Carcinogenesis 2007, 6:17 http://www.carcinogenesis.com/content/6/1/17
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non-transfected uveal melanoma cells, with and without
the addition of Amfenac.
Discussion
COX-2 expression has been identified in a wide variety of
human malignant tumors [10-12], including uveal
melanoma [7]. In previous work we have shown 58% of
human uveal melanomas to express COX-2 and this
expression was linked to histopathological markers of
poor prognosis, such as epithelioid cell type, vascular
closed loops and tumor infiltrating lymphocytes [7]. The
study by Figueiredo et al. gave insight into potential roles
for COX-2 in uveal melanoma, which we have proceeded
to investigate in the present in vitro studies. We also
sought to demonstrate the effects of a COX-2 inhibitor on
the proliferation and macrophage cytotoxic activity in
response to soluble factors secreted by the tumor cells.
COX-2 has been shown to play a role in proliferation in
vitro studies of prostate [28] and breast tumors [29]. The
present study showed that COX-2 transfected human uveal
melanoma cell lines had a higher proliferation rate com-
pared to their non-transfected counterparts with the excep-
tion of OCM-1. This increase in proliferation rate could be
attributed to a wide range of factors produced by the COX-
2 enzyme that could influence proliferation rates, such as
PGE2 [30]. Further investigation into the possible mecha-
nisms for this decrease in proliferation by OCM-1 after
expression of COX-2 is currently underway. It is interesting
to note that using the Sulforhodamine-B assay a decrease in
proliferation was seen for OCM-1 transfected with COX-2,
however a small increase in SPF% was seen when analyzed
by flow cytometry. Sulforhodamine-B measures the bio-
mass present in each well which may explain the difference
with the flow cytometry results.
The present study also showed that the addition of
amfenac, the active metabolite of Nepafenac which is a
COX-2 inhibitor [19,20], significantly decreased the prolif-
eration rate of all cell lines. What was perhaps even more
interesting was the fact that the addition of amfenac not
only decreased the proliferation rate of those cells that
expressed COX-2, but also the three cell lines that were
found to not express COX-2 after testing by immunohisto-
chemistry, and western blott analysis. This result supports
the growing body of literature showing a possible COX-2-
independent mechanisms of action for certain COX-2
inhibitors such as Celecoxib [9,31,32]. This lack of COX-2
expression in our non-transfected cell lines, despite COX-2
expression in the primary tumors of patients, may reflect
that the full tumor microenvironment is necessary for the
expression of COX-2 by these cells.
This study is also the first to investigate the effect of uveal
melanoma soluble factors on macrophage cytotoxic
potential. In uveal melanoma, the presence of tumor asso-
ciated macrophages (TAM) has previously been shown to
be an independent prognostic factor of poor prognosis
[5], suggesting that macrophages are not functioning in an
anti-tumor role. In vitro conditioned medium studies have
shown cutaneous melanoma cells to inhibit macrophage
tumoricidal activity [6,33] and that COX-2 inhibition was
shown to reverse the melanoma induced suppression of
macrophage cytotoxic activity [6]. A major mechanism of
cytotoxicity by macrophages is the production of nitric
oxide, which can be induced by a variety of stimuli such
as T-helper cytokines, bacterial wall component LPS, and
interferon γ [6]. For our study, we used both LPS and
interferon γ as both have previously been shown to stim-
ulate NO production by macrophages [34].
The addition of melanoma conditioned medium to mac-
rophages significantly inhibited the production of NO by
four of the five non-transfected human uveal melanoma
cell lines. It is interesting to note that the sole cell line that
did not significantly inhibit NO production was UW-1.
The addition of conditioned medium from the COX-2
transfected cell lines did not give significantly different
results for the four uveal melanoma cell lines. In compar-
ison, however, the UW-1 transfected cell line did give a
significant decrease in NO production compared to its
non-transfected counterpart. This cell line was established
from normal melanocytes whereas the other four cell lines
were established from the primary uveal melanoma
tumors of patients [22,23]. We suggest that the UW-1 cell
line behaved differently due to its origins as a transformed
melanocytic cell line. This cell line may never have had to
escape immune surveillance, and therefore did not induce
a decrease in NO production by macrophages. Further
investigation into the difference between conditioned
medium from UW-1 and conditioned medium from
uveal melanoma cell lines is currently underway.
The inhibitory effect of conditioned medium from the five
cell lines used on macrophage NO production was ranked
for both the transfected and non-transfected cells. In both
cases the inhibition was greatest with the SP6.5 and 92.1
cell lines, while OCM-1 and UW-1 gave the least inhibi-
tion, with MKT-BR ranking in the middle. This ranking is
the same as the proliferative and metastatic ranking of the
cell lines that has previously been described [21], indicat-
ing that those cell lines with the highest proliferative and
metastatic potential also are the ones with the greatest
ability to inhibit macrophage NO production.
We have previously demonstrated that a "cross-talk" exists
between uveal melanoma tumor cells and macrophages,
causing an up-regulation of several soluble factors such as
Vascular Endothelial Growth Factor, Interleukin-6, Hepa-
tocyte Growth Factor, and Melanoma Inhibitory ActivityJournal of Carcinogenesis 2007, 6:17 http://www.carcinogenesis.com/content/6/1/17
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[35-37]. These soluble factors have been shown play a role
in processes such as tumor proliferation, invasion and cel-
lular motility. The present study is the first to show an
inhibitory effect of uveal melanoma soluble factors on the
cytotoxic activity of macrophages. Further investigations
are warranted to identify the soluble factors responsible
for this uveal melanoma-induced suppression of macro-
phage function.
When the COX-2 inhibitor amfenac was added to the
MCM, the suppression of macrophage function was par-
tially overcome in all instances. The addition of amfenac
not only affected macrophages exposed to medium from
COX-2 transfected cells, but also macrophages exposed to
medium from non-transfected cells. This result again sup-
ports the hypothesis that amfenac may have a COX-2-
independent mechanism of action.
COX-2 inhibitors show promise for use as an adjuvant
therapy in many tumor types. However, there has been
recent discussion regarding the safety of systemic COX-2
inhibitors, most notably rofecoxib [38]. In our study, we
used amfenac, the active metabolite of Nepafenac. This
COX-2 inhibitor was formulated for topical administra-
tion and may present with a better systemic safety profile
than rofecoxib.
Production of NO by macrophages exposed to melanoma conditioned medium with and without the addition of amfenac Figure 3
Production of NO by macrophages exposed to melanoma conditioned medium with and without the addition of amfenac.
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In conclusion, COX-2 expressing uveal melanoma cell
lines demonstrated an increase in proliferation over their
non-COX-2 expressing counterparts. The anti-COX-2
molecule amfenac inhibited the proliferation rate of both
COX-2 expressing and non-expressing uveal melanoma
cell lines. In addition, amfenac partially overcame the
suppression of macrophage function by conditioned
medium from both COX-2 transfected and non-trans-
fected uveal melanoma cell lines. Further trials should be
undertaken to study the effect of COX-2 inhibitors as
potential adjuncts to standard therapy for uveal
melanoma and to investigate the potential COX-2 inde-
pendent function of amfenac.
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